Brief: Revive Therapeutics Explores The Use Of Bucillamine As A Novel Treatment For Infectious Diseases Including Covid-19
20/03/2020 10:02
March 20 (Reuters) - Revive Therapeutics Ltd RVV.CD :
* REVIVE THERAPEUTICS EXPLORES THE USE OF BUCILLAMINE AS A
NOVEL
TREATMENT FOR INFECTIOUS DISEASES INCLUDING COVID-19
Source text for Eikon: ID:nGNX2Ztx1q
Further company coverage: RVV.CD
((Briefs@thomsonreuters.com;))
Recent news on Revive Therapeutics
See all newsBrief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Announces Closing Of Second Tranche Of Private Placement
Brief: Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence
Brief: Revive Therapeutics Provides Update On Research Study Evaluating Bucillamine For Nerve Agent Exposure